Results for tag: "5 Hydroxytryptamine Receptor 2B"

The 5-Hydroxytryptamine Receptor 2B (5-HT2B) is a G-protein coupled receptor (GPCR) that is involved in the regulation of serotonin levels in the central nervous system (CNS). It is a target for the development of drugs to treat a variety of CNS disorders, including depression, anxiety, schizophrenia, and Alzheimer's disease. 5-HT2B agonists have been shown to have antidepressant and anxiolytic effects, while 5-HT2B antagonists have been shown to have antipsychotic effects. The 5-HT2B market is a rapidly growing segment of the CNS drug market, with a number of companies developing drugs targeting this receptor. Companies such as Allergan, Merck, and Pfizer are developing 5-HT2B agonists, while companies such as Otsuka Pharmaceuticals and Sunovion Pharmaceuticals are developing 5-HT2B antagonists. Other companies such as AstraZeneca, GlaxoSmithKline, and Novartis are also researching 5-HT2B drugs. Show Less Read more